Arkolith/Insider Trading/NAMS/Form 4

Kastelein Johannes Jacob Pieter

Chief Scientific Officer, DirectorNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Mar 9, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$9.1M
Net Open-Market Flow
-$9.1M
Transactions
9
6 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 9, 2026Sell(S)101K$30.29$3.1M69K
Mar 9, 2026Option exercise(M)101K——171K
Mar 6, 2026Option exercise(M)94K——163K
Mar 6, 2026Sell(S)94K$30.32$2.9M69K
Mar 5, 2026Option exercise(M)104K——174K
Mar 5, 2026Sell(S)104K$30.30$3.2M69K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 9, 2026Option exercise(M)101K—$0520K
Mar 6, 2026Option exercise(M)94K—$0622K
Mar 5, 2026Option exercise(M)104K—$0716K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-099073) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML